JAZZ vs. CRSP
JAZZ (Jazz Pharmaceuticals plc) and CRSP (CRISPR Therapeutics AG) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, JAZZ returned 5.88%/yr vs -14.40%/yr for CRSP. At a 0.30 correlation, their price movements are largely independent.
Performance
JAZZ vs. CRSP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JAZZ achieves a 35.84% return, which is significantly higher than CRSP's -0.69% return.
JAZZ
- 1D
- 2.13%
- 1M
- 10.99%
- YTD
- 35.84%
- 6M
- 38.20%
- 1Y
- 109.33%
- 3Y*
- 21.63%
- 5Y*
- 5.88%
- 10Y*
- 4.22%
CRSP
- 1D
- 0.12%
- 1M
- -2.80%
- YTD
- -0.69%
- 6M
- -6.98%
- 1Y
- 36.91%
- 3Y*
- -7.12%
- 5Y*
- -14.40%
- 10Y*
- —
JAZZ vs. CRSP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
JAZZ Jazz Pharmaceuticals plc | 35.84% | 38.04% | 0.12% | -22.79% | 25.05% | -22.81% | 10.56% | 20.43% | -7.94% | 23.50% |
CRSP CRISPR Therapeutics AG | -0.69% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 15.89% |
Correlation
The correlation between JAZZ and CRSP is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Oct 20, 2016 | 0.30 |
Fundamentals
JAZZ:
$15.26B
CRSP:
$5.00B
JAZZ:
$0.47
CRSP:
-$6.24
JAZZ:
3.25
CRSP:
1.16K
JAZZ:
3.37
CRSP:
2.76
JAZZ:
$4.44B
CRSP:
$4.10M
JAZZ:
$2.97B
CRSP:
-$171.17M
JAZZ:
$336.83M
CRSP:
-$509.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JAZZ vs. CRSP — Risk / Return Rank
JAZZ
CRSP
JAZZ vs. CRSP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| JAZZ | CRSP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.38 | ||
| Sortino ratioReturn per unit of downside risk | +3.26 | ||
| Omega ratioGain probability vs. loss probability | 1.57 | 1.15 | +0.43 |
| Calmar ratioReturn relative to maximum drawdown | 9.63 | 0.88 | +8.75 |
| Martin ratioReturn relative to average drawdown | 23.75 | 1.49 | +22.26 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| JAZZ | CRSP | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.98 | 0.60 | +2.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.19 | -0.24 | +0.43 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.13 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.19 | 0.23 | -0.04 |
Drawdowns
JAZZ vs. CRSP - Drawdown Comparison
The maximum JAZZ drawdown since its inception was -96.90%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for JAZZ and CRSP.
Loading charts...
Drawdown Indicators
| JAZZ | CRSP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.90% | -85.11% | -11.79% |
Max Drawdown (1Y)Largest decline over 1 year | -11.42% | -42.25% | +30.83% |
Max Drawdown (3Y)Largest decline over 3 years | -32.71% | -64.91% | +32.20% |
Max Drawdown (5Y)Largest decline over 5 years | -47.55% | -80.68% | +33.13% |
Max Drawdown (10Y)Largest decline over 10 years | -52.10% | — | — |
Current DrawdownCurrent decline from peak | -3.71% | -75.20% | +71.49% |
Average DrawdownAverage peak-to-trough decline | -27.42% | -49.17% | +21.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.62% | 24.92% | -20.30% |
Volatility
JAZZ vs. CRSP - Volatility Comparison
The current volatility for Jazz Pharmaceuticals plc (JAZZ) is 9.90%, while CRISPR Therapeutics AG (CRSP) has a volatility of 14.90%. This indicates that JAZZ experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JAZZ | CRSP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.90% | 14.90% | -5.00% |
Volatility (6M)Calculated over the trailing 6-month period | 23.47% | 42.49% | -19.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.89% | 61.68% | -24.79% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.75% | 60.46% | -28.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.77% | 64.27% | -31.50% |
Dividends
JAZZ vs. CRSP - Dividend Comparison
Neither JAZZ nor CRSP has paid dividends to shareholders.
Financials
JAZZ vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Jazz Pharmaceuticals plc and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
JAZZ and CRSP have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRSP has higher volatility (14.90%) compared to JAZZ (9.90%). In terms of maximum drawdown, JAZZ dropped -96.90% vs CRSP's -85.11%.
JAZZ currently has the higher Sharpe Ratio (2.98 vs 0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JAZZ and CRSP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer